HER2-Mutant NSCLC Drug Pipeline — PatSnap Eureka
HER2-Mutant NSCLC Drug Pipeline: ADCs, TKIs & Next-Generation Approaches
HER2 (ERBB2) mutations occur in approximately 2–4% of NSCLC cases — a molecularly distinct, historically underserved subset now at the centre of a rapidly evolving therapeutic pipeline spanning ADCs, allele-selective TKIs, bispecific antibodies, and cellular immunotherapy.
A Molecularly Distinct NSCLC Subset with Unmet Therapeutic Need
Non-small cell lung cancer accounts for approximately 80–85% of all lung cancer cases, with overall five-year survival rates for advanced disease of just 2–4%. Among the driver mutations that define molecularly stratified treatment populations — including EGFR, KRAS, ALK, MET, ROS1, and BRAF — HER2 (ERBB2) mutations appear as a biologically distinct subset with historically limited approved targeted therapy options.
HER2 mutation in NSCLC is distinct from HER2 amplification or overexpression (the paradigm in breast and gastric cancer). It involves point mutations in exons 19–20 of ERBB2 that activate kinase signalling without receptor overexpression — a distinction with direct implications for therapeutic strategy. The life sciences innovation intelligence captured in the PatSnap Eureka dataset confirms HER2-mutant tumours as a biologically distinct patient segment with significant unmet need, particularly in the acquired resistance context.
Key molecular targets surfacing in the broader dataset include HER2 (ERBB2) as a targetable mutation alongside EGFR, KRAS, and MET; MET exon 14 highlighted by Regeneron Pharmaceuticals as a bispecific antibody target; ALPP/ALPPL2 surface antigens identified by the University of Texas as ADC and CAR-T targets in treatment-resistant NSCLC; and the PD-L1/PD-1 axis as the immunotherapy backbone against which targeted modalities are increasingly combined.
Five Modality Classes Shaping the HER2-Mutant NSCLC Pipeline
Patent and literature signals from 2019–2025 identify five distinct therapeutic modality classes across preclinical and clinical development stages in HER2-mutant and driver-mutant NSCLC.
Antibody–Drug Conjugates (ADCs)
Two distinct ADC target axes are evidenced. The University of Texas System (WO, 2025) explicitly claims ADC approaches targeting ALPP and/or ALPPL2 in NSCLC harbouring HER2 mutations — a preclinical-stage concept addressing resistance mechanisms. MSD International Business GmbH (WO, 2025) covers sacituzumab govitecan (TROP-2 ADC) at 10 mg/kg IV weekly plus pembrolizumab, targeting an objective response rate of at least 44% in first-line metastatic NSCLC.
Advanced Clinical (SG) Preclinical (ALPP ADC)HER2-Targeted TKIs & Antibody Combinations
Seagen Inc. (SG, 2019) documents tucatinib — a HER2-selective oral TKI — combined with trastuzumab in gastric cancer PDX models (tucatinib 50 mg/kg PO BID + trastuzumab 20 mg/kg IV Q3D), establishing the structural template for HER2-mutant NSCLC extension. While zongertinib (BI-1810631) is not named in retrieved patent documents, the TKI/antibody combination paradigm is the framework against which next-generation allele-selective HER2 TKI development proceeds.
Clinical (HER2+ cancers)Bispecific Antibodies Targeting Driver Mutations
Regeneron Pharmaceuticals (US, 2024) discloses MET×MET bispecific antibody REGN5093 targeting NSCLC with MET exon 14 alterations, MET amplification, or MET overexpression. The filing explicitly notes that MET-driven NSCLC patients — analogous to HER2-mutant patients — may not equivalently benefit from PD-1/PD-L1 monotherapy, framing dual epitope engagement as the preferred intervention. This mechanistic framework directly parallels the therapeutic rationale being applied to HER2-mutant NSCLC.
Early Clinical (MET bispecific)CAR-T, CAR-NK & TIL Adoptive Cell Therapies
The University of Texas System (WO, 2025) claims CAR-T and CAR-NK cell therapies targeting ALPP/ALPPL2 in NSCLC harbouring HER2, EGFR, KRAS, MET, and other driver mutations. Iovance Biotherapeutics holds multiple patent families (US, CA, BR, IN, JP) covering tumour-infiltrating lymphocyte (TIL) therapy in patients refractory to anti-PD-1 antibody therapy — a clinically relevant salvage modality for HER2-mutant patients who have exhausted targeted therapy options.
Clinical (TIL) Preclinical (CAR-T)Pipeline Intelligence: Assignees, Targets & Combination Signals
Patent-derived data points from the HER2-mutant NSCLC dataset, visualised from the PatSnap Eureka patent and literature analysis.
Key Assignees by Jurisdiction Reach
Genentech/Roche and MedImmune/AstraZeneca are the most patent-active assignees in this dataset, each filing across 10+ jurisdictions in NSCLC-relevant modalities.
Emerging Combination Approach Signals
Five combination directions identified across the dataset, with ADC + anti-PD-1 combinations representing the most advanced clinical archetype.
Who is Filing in HER2-Mutant NSCLC? Key Organisations by Modality
| Assignee | Modality Focus | Key Filing(s) | Jurisdictions | Stage |
|---|---|---|---|---|
| Genentech / F. Hoffmann-La Roche AG | Immune checkpoint (tiragolumab + atezolizumab); biomarker-driven patient selection | Multiple families, AU 2025 | US, WO, AU, CA, MX, SG, IL, PE, NZ, CN, JP (10+) | Clinical |
| MedImmune / AstraZeneca | Durvalumab + tremelimumab; chemoradiotherapy + PD-L1 combinations | Multiple WO/EP/SG families | WO, SG, EP, GB, CA, AU, BR, MX, TW, HK, JP, CN (12+) | Clinical |
| MSD International Business GmbH / Merck | Sacituzumab govitecan (TROP-2 ADC) + anti-PD-1; necitumumab + pembrolizumab | WO 2025, US 2025 | WO, US | Advanced Clinical |
| Seagen Inc. | Tucatinib + trastuzumab HER2-directed TKI/mAb combination | SG 2019 | SG (WO) | Clinical |
Track every HER2-NSCLC filer in real time
PatSnap Eureka monitors 120+ patent offices and surfaces new assignee activity as it happens.
Key Clinical-Stage Evidence in the HER2-NSCLC Dataset
The clearest clinical-stage ADC + immunotherapy combination signal in this dataset is the sacituzumab govitecan (SG) + pembrolizumab filing from MSD International Business GmbH (WO/US, 2025). This Phase II/III-level filing targets an objective response rate of ≥44% in treatment-naive metastatic NSCLC receiving SG 10 mg/kg IV weekly on days 1 and 8 plus pembrolizumab 200 mg IV on day 1 of 21-day cycles. This constitutes a directly translatable framework for HER2-directed ADC combinations.
The tucatinib + trastuzumab combination (Seagen, SG 2019) provides PDX tumour volume data from gastric cancer model GXA 3054 (n=10) using tucatinib 50 mg/kg + trastuzumab 20 mg/kg, establishing preclinical proof-of-concept for the HER2 TKI/antibody combination. The patent analytics platform at PatSnap enables researchers to trace how this structural template has propagated into NSCLC-specific development programs.
The KRYSTAL-1 Phase II cohort (NCT03785249) evaluating adagrasib 600 mg BID in KRASG12C-mutant NSCLC (n=116; 98.3% received both prior chemotherapy and PD-1/PD-L1 therapy) establishes the Phase II methodological framework used across driver-mutant NSCLC programs — directly relevant to HER2-mutant trial design. ClinicalTrials.gov tracks the full landscape of ongoing HER2-directed NSCLC trials.
Notably, no retrieved results contain direct clinical trial data specifically for zongertinib or trastuzumab deruxtecan in HER2-mutant NSCLC — reflecting the bounded scope of this dataset. Core composition-of-matter IP for zongertinib likely resides in Boehringer Ingelheim's separately searchable portfolio. Researchers should expand searches to Boehringer Ingelheim-specific filings and ASCO/ESMO conference disclosures. See the PatSnap customer case studies for examples of competitive intelligence workflows used in oncology drug development.
What the Patent Record Signals for HER2-NSCLC Drug Developers
Five strategic signals derived from the patent and literature dataset with direct relevance to R&D strategy, IP positioning, and competitive intelligence in HER2-mutant NSCLC.
ADC Development is the Highest-Momentum Modality
ADC development is the highest-momentum modality in this dataset for driver-mutant NSCLC. Drug developers pursuing HER2-mutant NSCLC ADC IP should note that resistance antigen targeting (ALPP/ALPPL2) may represent a patentable white space distinct from direct HER2-epitope claims.
MET Bispecific Precedent as HER2 Bispecific Template
MET bispecific antibody precedent (Regeneron/REGN5093) provides a translatable IP and clinical development framework for HER2 bispecific approaches in NSCLC, particularly for HER2-mutant tumours where dual-epitope engagement could overcome ligand-independent signalling.
HER2-Mutant NSCLC Drug Pipeline — key questions answered
HER2 (ERBB2) mutations occur in approximately 2–4% of non-small cell lung cancer (NSCLC) cases and represent a distinct oncogenic driver subset historically underserved by approved targeted therapies.
HER2 mutation in NSCLC is distinct from HER2 amplification/overexpression (the paradigm in breast and gastric cancer), involving point mutations in exons 19–20 of ERBB2 that activate kinase signaling without receptor overexpression.
Two distinct ADC target axes are evidenced: HER2-directed and surface antigen-directed ADCs. The University of Texas System patent explicitly claims ADC approaches targeting ALPP and/or ALPPL2 in NSCLC harbouring HER2 mutations. The MSD patent covering sacituzumab govitecan (a TROP-2-directed ADC) in combination with an anti-PD-1 antibody targets an objective response rate of at least 44% in first-line metastatic NSCLC.
MSD International Business GmbH filing (WO, 2025) references a Phase II/III-level objective response rate target of ≥44% in treatment-naive metastatic NSCLC populations receiving SG 10 mg/kg IV weekly on days 1 and 8 plus pembrolizumab 200 mg IV on day 1 of 21-day cycles.
Regeneron Pharmaceuticals discloses MET×MET bispecific antibody (REGN5093) targeting NSCLC with MET exon 14 alterations, MET amplification, or MET overexpression. This mechanistic framework directly parallels the therapeutic rationale being applied to HER2-mutant NSCLC with bispecific and multi-specific formats, providing a translatable IP and clinical development framework for HER2 bispecific approaches in NSCLC.
PD-1/PD-L1 axis inhibition is consistently referenced across retrieved results as insufficient as monotherapy in driver-mutant NSCLC subsets (EGFR, ALK, MET, and by analogical extension HER2), creating a strong rationale for combination with HER2-directed agents. Developers should anticipate regulatory and trial design expectations for combination evidence rather than single-agent clinical strategies.
Still have questions about the HER2-NSCLC pipeline? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka Your Pipeline Questions →Accelerate Your HER2-NSCLC Drug Discovery with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search 2B+ data points across patents, literature, and clinical signals — instantly.
References
- Methods for the detection and treatment of resistant cancers co-expressing ALPP and/or ALPG/alppl2 — Board of Regents, The University of Texas System, 2025, WO [Patent]
- Treatment of HER2 positive cancers — Seagen Inc., 2019, SG [Patent]
- Treatment of non-small cell lung cancer using sacituzumab govitecan and an Anti-PD-1 antibody or antigen binding fragment thereof — MSD International Business GmbH, 2025, WO [Patent]
- Treatment of non-small cell lung cancer using sacituzumab govitecan and an Anti-PD-1 antibody or antigen binding fragment thereof — MSD International Business GmbH, 2025, US [Patent]
- Methods of treating non-small cell lung cancer using mesenchymal epithelial transition factor (MET)-targeted agents — Regeneron Pharmaceuticals, Inc., 2024, US [Patent]
- HDAC Inhibitors-Based Antibody Drug Conjugates (ADCs) and Use in Therapy — Alfasigma S.p.A., 2019, SG [Patent]
- Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies — Iovance Biotherapeutics, Inc., 2023, US [Patent]
- Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies — Iovance Biotherapeutics, Inc., 2022, CA [Patent]
- Treatment of NSCLC patients refractory to anti-PD-1 antibodies — Iovance Biotherapeutics, Inc., 2025, JP [Patent]
- Adagrasib: A landmark in the KRASG12C-mutated NSCLC — Jie He and Zhenlin Yang, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 2022 [Paper]
- KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer — Department of Thoracic Oncology, Hyogo Cancer Center, 2019 [Paper]
- Cancer Treatment Methods with Fc Alfa SIRPα Fusion in Combination with an Immune Checkpoint Inhibitor — ALX Oncology Inc., 2023, ID [Patent]
- Biomarkers and methods for treating NSCLC — Shanghai Junshi Biosciences Co., Ltd., 2023, WO [Patent]
- Prognostic and therapeutic methods for non-small cell lung cancer — Genentech, Inc., 2025, AU [Patent]
- Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies — F. Hoffmann-La Roche AG, 2019, WO [Patent]
- National Cancer Institute — Lung Cancer Information
- ClinicalTrials.gov — HER2-Mutant NSCLC Trials Registry
- World Health Organization — Cancer Classification and Epidemiology
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.